Keiichi Uchida, Kohei Otake, Mikihiro Inoue, Yuhki Koike, Kohei Matsushita, Koji Tanaka, Yasuhiro Inoue, Yasuhiko Mohri, Masato Kusunoki

Abstract: Purpose: The purpose of this study is to determine the presence of bacteriostatic effects of hyaluronan-based bioresorbable membrane (HA/CMC) on selected major bacterial strains in digestive organs. Methods: We firstly evaluated the growth inhibition effect of HA/CMC for E. coli and S. aureus by determining the optical density (OD)650 in the incubation medium. At second, to determine the viable counts of bacteria, total adenosine triphosphate (ATP) were measured with five groups; several concentrations of HA/CMC and control. Results: OD curve gradually elevated and reached to plateau at 4 hours in E. coli. and 6 hours in S. aureus. After reaching plateau, the growth inhibition of both strains was statistically significantly correlated to the concentrations of HA/CMC. The ATP productions had statistically significant differences at 6 hours after incubation and inhibited in dose-dependence of a well-dissolved HA/CMC. Conclusion: HA/CMC may have dose-dependently bacteriostatic effects on S. aureus and E. coli.

Keywords: HA/CMC, Bacteriostatic, Hyaluronan, Adhesion, Surgery

Cite this paper: nullK. Uchida, K. Otake, M. Inoue, Y. Koike, K. Matsushita, K. Tanaka, Y. Inoue, Y. Mohri and M. Kusunoki, "Bacteriostatic Effects of Hyaluronan-Based Bioresorbable Membrane," Surgical Science, Vol. 2 No. 9, 2011, pp. 431-436. doi: 10.4236/ss.2011.29094.

References

[1]   J. M. Becker, M. T. Dayton, V. W. Fazio, D. E. Beck, S. J. Stryker, S. D. Wexner, et al., “Prevention of Postoperative Abdominal Adhesions by a Sodium Hyaluronate-Based Bioresorbable Membrane: A Prospective, Randomized, Double-Blind Multicenter Study,” Journal of the American College of Surgeons, Vol. 183, No. 4, 1996, pp. 297-306.

[2]   Y. Mohri, K. Uchida, T. Araki, Y. Inoue, H. Tonouchi, C. Miki, et al., “Hyaluronic Acid-Carboxycellulose Membrane (Seprafilm?) Reduces Early Postoperative Small Bowel Obstruction in Gastrointestinal Surgery,” The American Surgeon, Vol. 71, No. 10, 2005, pp. 861-863.

[3]   M. Kusunoki, H. Ikeuchi, H. Yanagi, M. Noda, H. Tonouchi, Y. Mohri, et al., “Bioresorbable Hyaluronate-Carboxymethylcellulose Membrane (Seprafilm) in Surgery for Rectal Carcinoma: A Prospective Randomized Clinical Trial,” Surgery Today, Vol. 35, No. 11, 2005, pp. 940-945. doi:10.1007/s00595-005-3061-0

[4]   M. Inoue, K. Uchida, C. Miki and M. Kusunoki, “Efficacy of Seprafilm for Reducing Reoperative Risk in Pediatric Surgical Patients Undergoing Abdominal Surgery,” Journal of Pediatric Surgery, Vol. 40, No. 8, 2005, pp. 1301-1306. doi:10.1016/j.jpedsurg.2005.05.015

[5]   P. J. Klingler, N. R. Floch, M. H. Seelig, S. A. Branton, J. T. Wolfe and P. P. Metzger, “Seprafilm-Induced Peritoneal Inflammation: A Previously Unknown Complication―Report of a Case,” Diseases of the Colon & Rectum, Vol. 42, No. 12, 1999, pp. 1639-1643. doi:10.1007/BF02236221

[6]   F. H. Remzi, M. Oncel, J. M. Church, A. J. Senagore, C. P. Delaney and V. W. Fazio, “An Unusual Complication after Hyaluronate-Based Bioresorbable Membrane (Seprafilm) Application,” The American Surgeon, Vol. 69, No. 4, 2003, pp. 356-357.

[7]   A. O. Tzianabos, R. L. Cisneros, J. Gershkovich, J. Johnson, R. J. Miller, J. W. Burns, et al., “Effect of Surgical Adhesion Reduction Devices on the Propagation of Experimental Intra-Abdominal Infection,” Archives of Surgery, Vol. 134, No. 11, 1999, pp. 1254-1259. doi:10.1001/archsurg.134.11.1254

[8]   A. Tuzune, M. A. Kuzu, B. Akin, S. Karaca and S. Hazinedaroglu, “The Effect of Hyaluronan-Based Agents on Adhesion Formation in an Intra-Abdominal Sepsis Model,” Digestive Diseases and Sciences, Vol. 49, No. 6, 2004, pp. 1054-1061. doi:10.1023/B:DDAS.0000034571.30602.36

[9]   M. M. Reijnen, J. F. Meis, V. A. Postma and H. van Goor, “Prevention of Intra-Abdominal Abscesses and adhesions Using a Hyaluronic Acid Solution in a Rat Peritonitis Model,” Archives of Surgery, Vol. 134, No. 9, 1999, pp. 997-1001. doi:10.1001/archsurg.134.9.997

[10]   A. M. Ghellai, A. F. Stucchi, D. J. Lynch, K. C. Skinner, M. J. Colt and J. M. Becker, “Role of a Hyaluronate-Based Membrane in the Prevention of Peritonitis-Induced Adhesions,” Journal of Gastrointestinal Surgery, Vol. 4, No. 3, 2000, pp. 310-315. doi:10.1016/S1091-255X(00)80081-5

[11]   K. Uchida, H. Urata, Y. Mohri, M. Inoue, C. Miki and M. Kusunoki, “Seprafilm Does Not Aggravate Intraperitoneal Septic Conditions or Evoke Systemic Inflammatory Response,” Surgery Today, Vol. 35, No. 12, 2005, pp. 1054-1059. doi:10.1007/s00595-005-3085-5

[12]   K. Otake, K. Uchida, S. Yoshiyama, M. Inoue, Y. Okita, H. Watanabe, et al., “Effects of a Hyaluronate-Carboxy-Methylcellulose Membrane (Seprafilm) on Human Polymorphonuclear Neutrophil Functions,” Journal of Surgical Research, Vol. 149, No. 2, 2008, pp. 243-249. doi:10.1016/j.jss.2008.01.011

[13]   J. W. Burns, M. J. Colt, L. S. Burgees and K. C. Skinner, “Preclinical Evaluation of Seprafilm Bioresorbable Membrane,” European Journal of Surgery, No. 577, 1997, pp. 40-48.

[14]   B. P. Toole, In: D. E. Hay, Ed., Cell Biology of Extracellular Matrix, Plenum Press, New York, 1991, pp. 305-341.

[15]   C. N. Bertolami, “Glycosaminoglycan Interactions in Early Wound Repair,” In: T. K. Hunt, R. B. Heppenstall, E. Pines, et al., Eds., Soft and Hard Tissue Repair, Biological and Clinical Aspects, Praeger Publishers, New York, 1984, pp. 67-97.

[16]   G. A. Carlson, J. L. Dragoo, B. Samimi, D. A. Bruckner, G. W. Bernard, M. Hedrick, et al., “Bacteriostatic Properties of Biomatrices against Common Orthopaedic Pathogens,” Biochemical and Biophysical Research Communications, Vol. 321, No. 2, 2004, pp. 472-478. doi:10.1016/j.bbrc.2004.06.165

[17]   P. Pirnazar, L. Wolinsky, S. Nachnani, S. Haake, A. Pilloni and G. W. Bernard, “Bacteriostatic Effects of Hyaluronic Acid,” Journal of Periodontology, Vol. 70, No. 4, 1999, pp. 370-374. doi:10.1902/jop.1999.70.4.370

[18]   S. C. Hubbard and J. W. Burns, “Effects of a Hyaluronan-Based Membrane (Seprafilm) on Intraperitoneally Disseminated Human Colon Cancer Cell Growth in a Nude Mouse Model,” Diseases of the Colon & Rectum, Vol. 45, No. 3, 2002, pp. 334-344. doi:10.1007/s10350-004-6178-0

[19]   H. van Goor, J. S. de Graaf, K. Kooi, W. J. Sluiter, V. J. Bom, J. van der Meer, et al., “Effect of Recombinant Tissue Plasminogen Activator on Intra-Abdominal Abscess Formation in Rats with Generalized Peritonitis,” Journal of the American College of Surgeons, Vol. 179, No. 4, 1994, pp. 407-411.

[20]   D. I. McRitchie, D. Cummings and O. D. Rotstein, “Delayed Administration of Tissue Plasminogen Activator Reduces Intra-Abdominal Abscess Formation,” Archives of Surgery, Vol. 124, No. 12, 1989, pp. 1406-1410.

[21]   D. Foschi, L. Castoldi, E. Radaelli, P. Abelli, G. Calderini, A. Rastrelli, et al., “Hyaluronic Acid Pevents Oxygen Free-Radical Damage to Granulation Tissue: A Study in Rats,” International Journal of Tissue Reactions, Vol. 12, No. 6, 1990, pp. 333-339.

[22]   M. Akatsuka, Y. Yamamoto, K. Tobetto, T. Yasui and T. Ando, “Suppressive Effects of Hyaluronic Acid on Elastase Release from Rat Peritoneal Leucocytes,” Journal of Pharmacy and Pharmacology, Vol. 45, No. 2, 1993, pp. 110-114. doi:10.1111/j.2042-7158.1993.tb03693.x

[23]   D. Hiro, A. Ito, K. Matsuta and Y. Mori, “Hyaluronic Acid Is an Endogenous Inducer of Interleukin-1 Production by Human Monocytes and Rabbit Macrophages,” Biochemical and Biophysical Research Communications, Vol. 140, No. 2, 1986, pp. 715-722.

[24]   A. E. Moses, M. R. Wessels, K. Zalcman, S. Alberti, S. Natanson-Yaron, T. Menes, et al., “Relative Contributions of Hyaluronic Acid Capsule and M Protein to Virulence in a Mucoid Strain of the Group A Streptococcus,” Infection and Immunity, Vol. 65, No. 1, 1997, pp. 64-71.